Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Draupnir Bio logo — Bringing innovative therapies to patients

Draupnir Bio

Bringing innovative therapies to patients

Founded 2017 Denmark Denmark 16 employees Seed Total: $45.00M Biotechnology, Health Care +2

General Information

Company Name Draupnir Bio
Founded Year 2017
Location Denmark Denmark
Employees 16
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Draupnir Bio. To contact Draupnir Bio, visit draupnir.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Draupnir Bio compare?

A PDF of Draupnir Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Draupnir Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Draupnir Bio

Draupnir Bio is a Danish biotechnology company founded in 2017 with the slogan "Bringing innovative therapies to patients." The company is focused on developing oral, small molecule degraders of extracellular pathogenic proteins, which is a pioneering approach in the field of targeted protein degradation (TPD). This approach targets lysosome receptors and has the potential to revolutionize the TPD field by extending the potential of TPD to both extracellular and membrane-bound proteins. The company is led by a highly experienced team of pharma and biotech industry leaders and is a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany. Draupnir Bio has received a $33.00M Venture Round investment on 31 October 2019 from a syndicate of leading European investors including High-Tech Gründerfonds, Novo Holdings, Gilde Healthcare, Inkef. As a biotechnology company operating in the Biotechnology, Health Care, and Pharmaceutical industries, Draupnir Bio is dedicated to harnessing the natural machinery of the lysosome to develop innovative therapies and address unmet medical needs. With its differentiated proprietary technology platform, the company is poised to make significant advancements in the field of TPD, potentially offering new solutions for diseases that have historically been highly challenging to target with conventional therapies.

Business keywords: Therapeutics, Innovation, Cholesterol-lowering, Cardiovascular, Glycome exploration, Array technology, Protein chemistry, Carbohydrate chemistry, Heparan sulfate, Drug development, Infectious diseases, Research, Spin-out, Max-Planck Society

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round €12.00M 5
Novo Holdings Gilde Healthcare MP Healthcare Venture Management
Novo Holdings, Gilde Healthcare +3
17 Jul 2024
Venture Round $33.00M 4
Novo Holdings Gilde Healthcare Inkef
Novo Holdings, Gilde Healthcare +2
31 Oct 2019

Draupnir Bio Alternatives & Competitors

View All Alternatives
Draupnir Bio vs
Tacalyx GmbH
Tacalyx GmbH Germany

Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical ne...

Seed
17 employees
Biotechnology, Health Care
Draupnir Bio vs
Opsona Therapeutics
Opsona Therapeutics

Opsona Therapeutics is a leading drug development company specialising in the human immune system....

Series C
8 employees
Biotechnology, Health Care
Draupnir Bio vs
AN2 Therapeutics
AN2 Therapeutics United States

Developing therapies for rare, chronic, and serious infectious diseases

Grant
35 employees
Biotechnology, Health Care
View all alternatives

FAQ About Draupnir Bio

Bringing innovative therapies to patients
Draupnir Bio was founded in 2017.
Draupnir Bio is headquartered in Denmark.
Draupnir Bio operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on Therapeutics, Innovation, Cholesterol-lowering and Cardiovascular.
Draupnir Bio has approximately 16 employees.
Draupnir Bio has completed 2 funding rounds, raising a total of $45.00M. The latest funding stage is Seed.
Top alternatives and competitors to Draupnir Bio include Tacalyx GmbH, Opsona Therapeutics, AN2 Therapeutics, iN Therapeutics, Ousia Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Draupnir Bio and Tacalyx GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Draupnir Bio, https://bouncewatch.com/company/draupnir-bio, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes